RYTM - Rhythm Pharmaceuticals, Inc. - SEC Form 4 Insider Trading Screener
33 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2019-05-30 | RYTM | Van Der Ploeg Leonardus H.T. | Chief Scientific Officer | S - Sale+OE | $25.20 | -10,000 | 42,339 | -19% | -$252,050 | |||||
| DM | 2019-05-28 | RYTM | Van Der Ploeg Leonardus H.T. | Chief Scientific Officer | S - Sale+OE | $25.42 | -15,000 | 42,339 | -26% | -$381,350 | |||||
| M | 2019-03-15 | RYTM | Gottesdiener Keith Michael | CEO, Pres | S - Sale | $30.09 | -10,290 | 506,342 | -2% | -$309,647 | |||||
| M | 2019-03-13 | RYTM | Gottesdiener Keith Michael | CEO, Pres | S - Sale | $30.06 | -9,288 | 516,632 | -2% | -$279,182 | |||||
| M | 2019-02-26 | RYTM | Gottesdiener Keith Michael | CEO, Pres | S - Sale | $30.04 | -2,449 | 525,617 | 0% | -$73,571 | |||||
| M | 2019-02-15 | RYTM | Gottesdiener Keith Michael | CEO, Pres | S - Sale | $30.02 | -12,920 | 528,066 | -2% | -$387,886 | |||||
| D | 2019-02-13 | RYTM | Gottesdiener Keith Michael | CEO, Pres | S - Sale+OE | $30.00 | -3,934 | 540,986 | -1% | -$118,020 | |||||
| M | 2019-01-22 | RYTM | Gottesdiener Keith Michael | CEO, Pres | S - Sale | $30.05 | -15,779 | 544,920 | -3% | -$474,176 | |||||
2019-01-18 | RYTM | Gottesdiener Keith Michael | CEO, Pres | S - Sale | $30.01 | -10,115 | 560,699 | -2% | -$303,551 | ||||||
2019-01-16 | RYTM | Van Der Ploeg Leonardus H.T. | Chief Scientific Officer | S - Sale | $30.00 | -200 | 42,339 | 0% | -$6,000 | ||||||
2019-01-16 | RYTM | Gottesdiener Keith Michael | CEO, Pres | S - Sale | $30.00 | -662 | 570,814 | 0% | -$19,860 | ||||||
2018-12-03 | RYTM | Gottesdiener Keith Michael | CEO, Pres | S - Sale | $30.00 | -563 | 571,476 | 0% | -$16,890 | ||||||
2018-11-02 | RYTM | Gottesdiener Keith Michael | CEO, Pres | S - Sale | $30.08 | -16,500 | 572,039 | -3% | -$496,320 | ||||||
| D | 2018-11-02 | RYTM | Van Der Ploeg Leonardus H.T. | Chief Scientific Officer | S - Sale+OE | $30.09 | -38,000 | 42,539 | -47% | -$1,143,420 | |||||
| D | 2018-09-25 | RYTM | Van Der Ploeg Leonardus H.T. | Chief Scientific Officer | S - Sale+OE | $29.80 | -31,800 | 52,339 | -38% | -$947,540 | |||||
2018-05-22 | RYTM | Orbimed Advisors LLC | See Remarks, 10% | S - Sale | $30.43 | -19,580 | 2,750,079 | -1% | -$595,768 | ||||||
| M | 2018-05-18 | RYTM | Orbimed Advisors LLC | 10% | S - Sale | $30.88 | -131,636 | 2,769,659 | -5% | -$4,065,440 | |||||
| D | 2017-10-10 | RYTM | Mpm Bioventures V, L.P. | 10% | P - Purchase | $17.00 | +100,000 | 2,696,392 | +4% | +$1,700,000 | |||||
| D | 2017-10-10 | RYTM | Foley Todd | Dir, 10% | P - Purchase | $17.00 | +100,000 | 2,696,392 | +4% | +$1,700,000 | |||||
| D | 2017-10-10 | RYTM | Viswanathan Ravi | 10% | P - Purchase | $17.00 | +550,000 | 4,909,956 | +13% | +$9,350,000 | |||||
| D | 2017-10-10 | RYTM | Sandell Scott D | 10% | P - Purchase | $17.00 | +550,000 | 4,909,956 | +13% | +$9,350,000 | |||||
| D | 2017-10-10 | RYTM | Mott David M | 10% | P - Purchase | $17.00 | +550,000 | 4,909,956 | +13% | +$9,350,000 | |||||
| D | 2017-10-10 | RYTM | Kerins Patrick J | 10% | P - Purchase | $17.00 | +550,000 | 4,909,956 | +13% | +$9,350,000 | |||||
| D | 2017-10-10 | RYTM | Baskett Forest | 10% | P - Purchase | $17.00 | +550,000 | 4,909,956 | +13% | +$9,350,000 | |||||
| D | 2017-10-10 | RYTM | Barris Peter J | 10% | P - Purchase | $17.00 | +550,000 | 4,909,956 | +13% | +$9,350,000 | |||||
| D | 2017-10-10 | RYTM | Barrett M James | 10% | P - Purchase | $17.00 | +550,000 | 4,909,956 | +13% | +$9,350,000 | |||||
| D | 2017-10-10 | RYTM | New Enterprise Associates 13 LP | 10% | P - Purchase | $17.00 | +550,000 | 4,909,956 | +13% | +$9,350,000 | |||||
| D | 2017-10-10 | RYTM | Meeker David P | Dir | P - Purchase | $17.00 | +25,000 | 101,335 | +33% | +$425,000 | |||||
| D | 2017-10-10 | RYTM | Pfizer Inc | 10% | P - Purchase | $17.00 | +40,000 | 1,427,639 | +3% | +$680,000 | |||||
| D | 2017-10-10 | RYTM | Ipsen, S.A. | 10% | P - Purchase | $17.00 | +20,000 | 1,646,198 | +1% | +$340,000 | |||||
| D | 2017-10-10 | RYTM | Orbimed Advisors LLC | 10% | P - Purchase | $17.00 | +355,000 | 2,901,295 | +14% | +$6,035,000 | |||||
| D | 2017-10-10 | RYTM | Flynn James E | Possible Member of 10% Group, 10% | P - Purchase | $17.00 | +355,000 | 937,010 | +61% | +$6,035,000 | |||||
| D | 2017-10-05 | RYTM | Baker Bros. Advisors LP | Former 10% owner | P - Purchase | $17.00 | +885,000 | 1,878,242 | +89% | +$15,045,000 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |